Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

Sang Ook Ha1†, Hyoung Soo Kim2†, Sunghoon Park3*, Ki-Suck Jung3, Seung Hun Jang3, Sang Jin Han4, Hyun-Sook Kim4 and Sun Hee Lee2

Abstract
The reported survival rates of patients with acute respiratory distress syndrome (ARDS) caused by human adenovirus (HAdV) pneumonia are poor. The results do not differ much in immunocompetent patients supported by extracorporeal membrane oxygenation (ECMO). We report two immunocompetent patients with severe ARDS complicating HAdV pneumonia who were treated successfully and survived to discharge. Compared with previous cases, our cases might have benefited from several factors. First, the time interval between mechanical ventilator support and ECMO implantation was shorter. Second, we implemented conservative fluid management as recommended by the ARDS network using continuous renal replacement therapy (CRRT). Third, we administered an antiviral agent as early as possible. A clinical trial of early ECMO with CRRT and the administration of cidofovir in patients with severe ARDS complicating HAdV pneumonia are needed to confirm our results.

Keywords: Adenovirus, Cidofovir, Continuous renal replacement therapy, Extracorporeal membrane oxygenation

Background
Severe acute respiratory distress syndrome (ARDS) complicating adenovirus pneumonia has been a concern in immunocompetent adults since CDC (2001) reported two adenovirus pneumonia-related deaths in 2001. Previously, human adenovirus (HAdV) serotypes 3 and 7 accounted for the majority of severe infections; however, serotype 55 was recently identified as a pathogen of acute fatal pneumonia in immunocompetent adults (Yang et al. 2009; Kajon et al. 2010; Gu et al. 2012; Zhang et al. 2012; Cao et al. 2014). Although the mortality rate of HAdV pneumonia varies according to the study population and disease severity, a systemic review reported a mortality rate of 57.0%.

Extracorporeal membrane oxygenation (ECMO) has been used as rescue therapy for patients with severe ARDS caused by HAdV, but the outcome was not satisfactory (Gu et al. 2012; Sun et al. 2014; Prodhan et al. 2014). However, the greatest benefit of ECMO is protecting the lungs from high-pressure mechanical ventilation and oxygen toxicity, minimizing on-going lung injury. Additionally, several studies have reported that among ECMO survivors, CRRT groups had a better fluid balance compared with non-CRRT groups (Cavagnaro et al. 2007; Hoover et al. 2008; Blijdorp et al. 2009), and fluid overload at the end of ECMO was a predictor of a worse outcome (Gbadegesin et al. 2009). We believe that a low tidal volume and conservative fluid strategies are important for ARDS patients, and could be achieved by the early initiation of ECMO support and CRRT. We present two cases of severe ARDS caused by HAdV pneumonia for whom the early initiation of ECMO plus CRRT, together with an antiviral agent (cidofovir), was tried.
Methods

The patient data were evaluated with the approval of the Institutional Review Board of the author’s hospital. Due to the purely observational, retrospective, and non-interventional nature of this study, informed consent was deemed unnecessary and was not obtained. Patient records and information were anonymized and de-identified before analysis.

Between January and May 2015, three immunocompetent adults (a 32-year-old man, 46-year-old woman, and 60-year-old man) with HAdV pneumonia were admitted to Hallym University Sacred Heart Hospital. Two of these patients were transferred to the ICU, because of severe refractory hypoxemia and our ECMO team was consulted. Severe ARDS was diagnosed using the Berlin criteria (Fergusson et al. 2012): (1) new onset of respiratory symptoms within 1 week, or new or worsening symptoms during the previous week; (2) bilateral opacities on a chest radiograph or computed tomography (CT), not fully explained by pleural effusions, lobar/lung collapse, or nodules; (3) respiratory failure not fully explained by cardiac failure or fluid overload; and (4) an arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2) ratio ≤100 mmHg on ventilator settings that include positive end-expiratory pressure (PEEP) >5 cm H2O. HAdV pneumonia was diagnosed when the following criteria were met: (1) symptoms of an acute (viral) lower respiratory tract illness; (2) newly developed lung infiltration on chest radiography or CT; and (3) detection of adenovirus DNA from sputum specimens or bronchoalveolar lavage (BAL) fluid using the polymerase chain reaction (PCR).

ECMO and CRRT Management

Two patients required veno-venous (VV) ECMO support based on the following criteria: good premorbid functioning, PaO2/FiO2 <100 on FiO2 1.0 with a PEEP of >15 cm H2O or uncompensated hypercapnia with acidemia (pH < 7.25); and a high end-inspiratory plateau pressure (>35 cm Hg) despite application of the best standard care using a mechanical ventilator. The Centrifugal Rotaflow Pump® (Maquet, Hirrlingen, Germany) and 17–21Fr venous cannulas (DLP®, Medtronic or RMI®; Edward’s Lifesciences, Irvine, CA, USA) were used. Both common femoral veins were cannulated percutaneously using the Seldinger technique guided by fluoroscopy in the cardiac catheterization laboratory. During ECMO, nafamostat mesilate (SK Chemicals Life Science, Seoul, Korea licensed by Torii Pharmaceutical, Tokyo, Japan) was used for anticoagulation with a maintenance dose of 0.4–1.5 mg/kg/h and a target activated partial thromboplastin time (aPTT) of 60–80 s. The CRRT machine was introduced into the ECMO circuit by connecting the inlet line after the oxygenator and the outlet line before the oxygenator (Chen et al. 2014). The mechanical ventilator settings were as follows: inspiratory pressure, 10 cm H2O; PEEP, 10 cm H2O; respiration rate, 10/min; I/E ratio, 2:1; and FiO2, 0.21–0.6. The target hematocrit was >30% and the platelet target >50,000–100,000/mm3. Although a positive fluid balance was initially permitted up to 2–3 L/day due to the patients’ unstable hemodynamic conditions, a conservative fluid strategy, as recommended by the ARDS Clinical Trial Network, was followed thereafter (National Heart L et al. 2006; Brodie and Bacchetta 2011). Successful ECMO weaning was defined as patient survival for >24 h after ECMO removal.

Results

Patient 1

A 46-year-old healthy woman with a non-contributory medical history had a high fever, cough, and sputum for 5 days and was admitted to a local hospital with left lower lobe pneumonia. Despite administration of empirical antibiotic therapy comprising intravenous ceftriaxone and clarithromycin, her symptoms persisted and she developed dyspnea; at this time the patient was referred to our hospital (Fig. 1). On admission, her vital signs were systolic blood pressure 120 mm Hg, heart rate 104 beats/min, respiratory rate 24/min, and body temperature 39 °C. The white blood cell count was 11,900/mm3, C-reactive protein was 162.2 mg/L, and liver function tests were within normal ranges. By pulse oximetry, the initial oxygen saturation was 89% with O2 8 L via facial mask. On the second day of hospitalization, the consolidation on chest X-ray was worse and her oxygen requirement markedly increased. She was transferred to the ICU and started on mechanical ventilation and a norepinephrine infusion (~0.6 μg/kg/min; Simplified Acute Physiologic Score II [SAPS II], 35). On ICU day 2, HAdV was identified by PCR in a sputum specimen obtained at the time of admission, and she was given cidofovir 5 mL/kg/week for 2 weeks. We also started intravenous methylprednisolone at 1 mg/kg q 24 h, which was later tapered slowly. However, the severe hypoxia was not improved despite a FiO2 of 100% and a PEEP of 15 cm H2O (i.e., PaO2/FiO2 = 40 mmHg), and her plateau pressure was >35 mm H2O. We put her in a prone position, but this did not improve her severe hypoxemia. Therefore, we started VV ECMO in the patient with concomitant CRRT. The initial ECMO settings were as follows: blood flow 4.6 L/min, sweep gas flow 6.0 L/min, and FiO2 1.0 (Table 1). Her hemodynamic findings stabilized after initiating VV ECMO. We performed BAL, and the cell differential in the BAL fluid was as follows: neutrophils 45%, lymphocytes 26%, macrophages 20%, and eosinophils 9%. Microbiological testing of the BAL specimen gave a positive PCR test for HAdV, while all tests for bacteria and other
viruses were negative. We continued the conservative fluid strategy throughout the ECMO treatment (Table 2) and her chest X-ray findings began to improve on ECMO day 4. She was extubated and allowed to awaken from the ECMO on day 5. On ICU day 16 (i.e., ECMO day 14), ECMO and CRRT were finally weaned and removed. Her net fluid balance was $-2305 \text{ mL} (-164.6 \text{ mL/day})$ during the ECMO period (Fig. 2). Subsequently, she was transferred to a general ward on ICU day 20 and finally discharged home. She was alive and had normal daily activities at the 1-year follow-up assessment.

**Patient 2**

A 60-year-old man with a history of hypertension, variant angina, and hyperthyroidism developed high fever, cough, sputum, myalgia and dyspnea 4 days before admission. He was admitted to our hospital with a presumptive diagnosis of community-acquired pneumonia and treated with empirical antibiotic therapy comprising piperacillin–tazobactam and levofloxacin (Fig. 1). His systolic blood pressure was 100 mm Hg, heart rate 126 beats/min, respiratory rate 36/min, and body temperature 39 °C. The initial laboratory findings were as follows: WBC 14,500/mm$^3$, platelets 237,000/mm$^3$, CRP 302.6 mg/L, BUN 29.8 mg/dL, and creatinine 1.18 mg/dL. Liver function tests were within normal ranges. The initial $\text{O}_2$ saturation was 85% and he received $\text{O}_2$ (5 L/min) via facial mask. On day 3, his chest X-ray findings were worse and his oxygen requirement was increased. The patient was transferred to the ICU and treated with a non-invasive positive pressure ventilator. However, his severe hypoxemia was not improved ($\text{SaO}_2 = 94\%$ with $\text{FiO}_2 100\%$ and respiratory rate = 45/min), and he was intubated. On ICU day 2, his severe hypoxemia was not improved despite mechanical ventilation (i.e., $\text{PaO}_2/\text{FiO}_2 = 67.6$ with a PEEP of 15 cm H$_2$O), and his heart rate increased to 151 beats/min (SAPS II, 36). We decided to apply VV ECMO, and started CRRT for fluid management. The initial ECMO settings were as follows: blood flow 5.0 L/min, sweep gas flow 4.5 L/min, and FiO$_2$ 1.0. On ECMO day 4, a PCR test for HAdV in a sputum sample taken at the time of admission was positive; based on this finding, the patient was administered cidofovir 5 mL/kg/week. The cell differential in the BAL fluid was as follows: neutrophils 43%, lymphocytes 34%, macrophage 22%, and eosinophils 1%. All tests of the BAL specimen for bacteria and viruses were negative. Although his blood gas oxygenation and chest X-ray showed an initial improvement during the early period of VV ECMO support, they were again worse on ECMO day 7 (Fig. 1).
Therefore, we started treatment with methylprednisolone 2 mg/kg q 24 h, which was then tapered slowly. We attempted to maintain a conservative fluid strategy (Table 2) and the PaO₂/FiO₂ ratio and chest X-ray findings began to improve from ECMO day 9. On ECMO day 12, a tracheostomy was performed and ECMO and CRRT were removed on ECMO day 24. His net fluid balance was +10,219 mL (+425.8 mL/day) throughout the ECMO treatment (Fig. 2). The patient was transferred to a general ward on ICU day 32 and finally discharged home. At his 1-year follow-up assessment, the patient was ambulatory and able to perform light housework.

Discussion
We successfully treated two patients diagnosed with adenovirus pneumonia with severe ARDS and suggest that such patients might benefit from early appropriate support using VV ECMO and CRRT.

Although no well-designed randomized controlled trials have proven its efficacy (Zapol et al. 1979; Morris et al. 1994, 2012), the conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR) trial and 2009 influenza A (H1N1) epidemic have promoted ECMO use worldwide (Peek et al. 2009; ANZ ECMO et al. 2009). To date, several authors have reported ECMO use in severe ARDS caused by HAdV. Sun et al. (2014) described five patients with severe ARDS with confirmed HAdV-55 infection, four of whom received VV ECMO. Low et al. (2013) reported three patients with confirmed HAdV-7 ARDS who were treated with VV ECMO; the reported survival rates were poor. Prodhan et al. (2014) also reported that only 62 (38.0%) of 163 children with adenovirus pneumonia supported using ECMO survived. However, both of our patients survived throughout the period of ECMO support. Compared with previous studies, our cases might have benefited from several factors. First, the time interval between mechanical ventilator support and ECMO implantation was shorter. Second, we followed the conservative fluid management recommended by the

### Table 1 Clinical and hemodynamic parameters of two patients

|                      | Pre-ECMO | ECMO day 1 | ECMO day 3 | ECMO day 7 | ECMO day 10 | ECMO day 14 | Post ECMO weaning |
|----------------------|----------|------------|------------|------------|-------------|-------------|------------------|
| **Patient 1**        |          |            |            |            |             |             |                  |
| Arterial blood gas analysis |          |            |            |            |             |             |                  |
| pH                   | 7.40     | 7.49       | 7.464      | 7.46       | 7.43        | 7.44        | 7.40             |
| PaCO₂, mmHg          | 26.8     | 25.8       | 33.7       | 29.7       | 38.5        | 34.1        | 27.9             |
| PaO₂, mmHg           | 54.8     | 215.7      | 126.8      | 102.9      | 162.4       | 102.2       | 97.4             |
| SaO₂, %              | 86.7     | 99.9       | 98.8       | 98.4       | 99.9        | 98.1        | 97.9             |
| Mechanical ventilation |          |            |            |            |             |             |                  |
| Ins pressure, mmHg   | 18       | 10         | 10         | –          | –           | –           | –                |
| PEEP, mmHg           | 15       | 10         | 10         | –          | –           | –           | –                |
| FiO₂                 | 0.3      | 0.3        | 0.3        | 0.3 by NC  | 0.3 by NC   | 0.3 by NC   | 0.3 by NC        |
| ECMO blood flow, L/min | –       | 4.6        | 4.5        | 4.4        | 3.0         | 2.0         | –                |
| ECMO FiO₂            | –        | 1.0        | 1.0        | 1.0        | 1.0         | 0.2         | –                |
| Sweep gas flow, L/min | –       | 6.0        | 4.0        | 4.0        | 4.0         | 0           | –                |
| **Patient 2**        |          |            |            |            |             |             |                  |
| Arterial blood gas analysis |          |            |            |            |             |             |                  |
| pH                   | 7.38     | 7.42       | 7.43       | 7.47       | 7.45        | 7.46        | 7.41             |
| PaCO₂, mmHg          | 33.5     | 30.8       | 32.9       | 35.1       | 40.0        | 32.7        | 38.6             |
| PaO₂, mmHg           | 67.6     | 183.8      | 148.4      | 77.3       | 78.5        | 101.5       | 107.2            |
| SaO₂, %              | 92.5     | 99.9       | 99.6       | 96.0       | 96.0        | 98.3        | 97.5             |
| Mechanical ventilation |          |            |            |            |             |             |                  |
| Ins pressure, mmHg   | 20       | 10         | 10         | 10         | 8           | 6           | 6                |
| PEEP, mmHg           | 15       | 10         | 10         | 10         | 8           | 6           | 6                |
| FiO₂                 | 0.9      | 0.6        | 0.35       | 0.45       | 0.45        | 0.45        | 0.35             |
| ECMO blood flow, L/min | –       | 5          | 5          | 4.58       | 2.5         | 3.4         | –                |
| ECMO FiO₂            | –        | 1.0        | 1.0        | 1.0        | 1.0         | 1.0         | –                |
| Sweep gas flow, L/min | –       | 4.5        | 4.5        | 9.5        | 6.5         | 5.8         | –                |

ECMO extracorporeal membrane oxygenation, NC nasal cannula
Table 2  Hemodynamic and fluid balance parameters

|                    | Pre-ECMO | ECMO days |          |          |          |          |          |          |          |          |          | ECMO weaning day |
|--------------------|----------|-----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|------------------|
|                    |          | Day 1     | Day 3    | Day 5    | Day 7    | Day 9    | Day 11   | Day 13   | Day 15   | Day 17   | Day 19   | Day 21            |
| Blood pressure, mmHg| 100/57   | 92/64     | 133/77   | 118/80   | 130/79   | 124/71   | 93/50    | 101/53   | –        | –        | –        | –                 |
| Heart rate/min      | 82       | 87        | 82       | 90       | 104      | 99       | 89       | 91       | –        | –        | –        | –                 |
| Input, mL           | –        | 3905      | 4135     | 2750     | 4060     | 3060     | 3340     | 5700     | –        | –        | –        | –                 |
| Output, mL          | –        | 3435      | 4908     | 4898     | 2958     | 5340     | 3090     | 3957     | –        | –        | –        | –                 |
| CVP, cm H2O         | 17       | 13        | 16       | 15       | 8        | 5        | 1        | 1        | –        | –        | –        | –                 |
| BNP, pg/mL          | 152.4    | 117.2     | 656.0    | 187.1    | 84.1     | 60.3     | 37.14    | 22.15    | –        | –        | –        | –                 |
| Lactate, mmol/L     | 1.4      | 1.3       | 2.6      | 2.4      | 1.9      | 1.2      | 1.1      | 0.9      | –        | –        | –        | –                 |

Patient 2

| Blood pressure, mmHg| 115/78  | 163/95   | 131/77   | 114/63   | 143/84   | 105/68   | 159/95   | 130/74   | 117/69   | 116/71   | 105/62   | 127/84   | 128/102 |
| Heart rate/min      | 151     | 95       | 80       | 90       | 69       | 80       | 166      | 93       | 86       | 90       | 100      | 94       | 110     |
| Input, mL           | –       | 3364     | 5876     | 3125     | 2925     | 3045     | 3680     | 3505     | 3550     | 3620     | 3940     | 4045     | 3875    |
| Output, mL          | –       | 2120     | 4213     | 3992     | 2308     | 3870     | 2822     | 3099     | 3316     | 3215     | 3245     | 4633     | 2638    |
| CVP, cm H2O         | 17      | 18       | 17       | 17       | 10       | 8        | 9        | 8        | 5        | 7        | 7        | 6        | 7       |
| BNP, pg/mL          | 59.0    | 253.9    | 587.0    | 507.0    | 297.9    | 79.1     | 13.4     | 23.4     | 20.9     | 16.4     | 27.8     | 43.3     | 73.4    |
| Lactate, mmol/L     | 3.8     | 2.5      | 17       | 1.6      | 2.0      | 1.6      | 1.8      | 1.8      | 1.8      | 1.9      | 2.5      | 2.4      | 2.3     |

*BNP* brain natriuretic peptide, *CVP* central venous pressure
ARDS network, using CRRT support. Third, we administered the antiviral agent as early as possible.

The most important role of ECMO support might be ‘lung rest’ with a low tidal volume, thereby decreasing ventilator-induced lung injury (VILI). Therefore, the early initiation of ECMO seems to be an intriguing option to protect the lungs of these critically ill patients (MacLaren et al. 2012; Turner and Cheifetz 2013). In a case series in Low et al. (2013), the duration of pre-ECMO mechanical ventilation was 2, 5, and 16 days, while in Sun et al. (2014), it was 2–13 days, which were longer than in our two cases (i.e., 47 and 15 h, respectively). We also applied lung rest ventilation to the patients, as recommended by the Extracorporeal Life Support Organization (ELSO). Hence, we suggest that this early initiation of ECMO support might have played a role in our cases. However, ECMO has not been accepted as an established treatment for adults with ARDS (Morris et al. 2010; Hirshberg et al. 2013; Deutschman and Neligan 2016). Two randomized clinical trials failed to show that ECMO was efficacious in adults with ARDS (Zapol et al. 1979; Morris et al. 1994). Hence, we cannot say that ECMO treatment was directly related to patient survival in our cases. However, conservative fluid management using CRRT could have played a critical role in our cases. In a case series, Wolf et al. (2013) were concerned about precipitating intravascular depletion by CRRT at a time of maximal capillary leakage, we permitted, if needed, a positive fluid balance of up to 2–3 L in our cases on ECMO days 1–2. However, the total net fluid balance of the two cases during the entire ECMO period was −164.6 to 425.8 mL/day, respectively.

Regarding the treatment of severe HAdV pneumonia, no controlled trials have demonstrated the effectiveness of antiviral agents. Recently, Kim et al. (2015) reported that six patients with severe HAdV pneumonia who had received cidofovir a median of 7.1 days after symptom onset recovered to discharge. They suggested that the early administration of cidofovir is an important treatment option, especially in cases of HAdV-55 infection. In previous reports, however, many cases with HAdV infections did not receive cidofovir, and the few patients who received the agent had poor outcomes. In our cases, the time interval from symptom onset to cidofovir administration was 8–9 days, respectively. However, the clinical, radiological, and laboratory findings of our patients improved gradually. The only adverse reaction was a skin rash in one patient. The effectiveness of cidofovir for severe HAdV pneumonia should be investigated further.

There were several limitations to this study. First, only two patients were reviewed due to the rarity of patients with HAdV pneumonia who receive ECMO support. Therefore, more experience is needed to draw a firm conclusion regarding the standard therapy. Second, the HAdV serotypes were not identified in our patients; therefore, the clinical efficacy of cidofovir for pneumonia caused by HAdV of specific serotypes could not be
determined. Despite these limitations, however, we sug-
ggest that to reduce VILI and extravascular lung water, 
early initiation of concomitant VV ECMO and CRRT 
support should be considered in patients with severe 
ARDS complicating HAdV pneumonia.

Conclusions
We report two patients with severe ARDS complicating 
HAdV pneumonia who were treated successfully and 
survived to discharge. We suggest that this patient group 
might benefit from early appropriate support with VV 
ECMO plus CRRT and cidofovir administration. Further 
clinical analysis of this treatment strategy is needed to 
confirm our results.

Abbreviations
ARDS: acute respiratory distress syndrome; BAL: bronchoalveolar lavage; 
CESAR: conventional ventilatory support versus extracorporeal membrane 
    oxygenation for severe adult respiratory failure; CRRT: continuous renal 
    replacement therapy; CT: computed tomography; ECMO: extracorporeal 
    membrane oxygenation; ELSO: Extracorporeal Life Support Organization; 
HAdVs: human adenovirus; ICU: intensive care unit; PEEP: positive end expira-
tory pressure; PCR: polymerase chain reaction; SAPS: simplified acute physiol-
omy score; VILI: ventilator-induced lung injury; VV: veno-venous.

Authors’ contributions
SOH and HSK conceived and designed the study, interpreted data and helped 
draft the manuscript. SHP was responsible for the design and conduct of the 
study, data interpretation, preparation, and review and approval of the manu-
script. KSJ, SHJ, SJH and HSK and SHL contributed substantially to the study 
design, data analysis and interpretation, and the writing of the manuscript. All 
authors read and approved the final manuscript.

Author details
1 Department of Emergency Medicine, Hallym University Medical Center, Hal-
lym University Sacred Heart Hospital, Anyang-si, Korea. 2 Thoracic and Cardio-
vascular Surgery, Hallym University Medical Center, Hallym University Sacred 
Heart Hospital, Anyang-si, Korea. 3 Division of Pulmonary, Allergy and Critical 
Care Medicine, Department of Internal Medicine, Hallym University Medical 
Center, Hallym University Sacred Heart Hospital, 22, Gwanpyeong-ro 170 
beon-gil, Donan-gu, Anyang-si, Gyeonggi-do 431-070, Korea. 4 Division of Car-
diology, Department of Internal Medicine, Hallym University Medical Center, 
Hallym University Sacred Heart Hospital, Anyang-si, Korea.

Acknowledgements
None.

Competing interests
The authors declare that they have no competing interests.

Received: 31 January 2016 Accepted: 18 October 2016 
Published online: 03 November 2016

References
Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ 
ECMO) Influenza Investigators, Davies A, Jones D, Bailey M, Beca J, Bel-
Iomo R, Blackwell N, Forrest P, Gattas D, Granger E, Herkes R, Jackson A, 
McGuinness S, Naq P, Pellegrino V, Pettilä V, Plunkett B, Pye R, Tzirillo P, 
Webb S, Wilson M, Ziegenfuß M (2009) Extracorporeal membrane oxy-
genation for 2009 influenza A(H1N1) acute respiratory distress syndrome. 
JAMA 302:1888–1895

Blijdorp K, Cranisberg K, Wildschut ED, Gischler SJ, Jan Hounes R, Wolff ED, Tib-
boel D (2009) Haemofiltration in newborns treated with extracorporeal 
membrane oxygenation: a case-comparison study. Crit Care 13:R48

Brodie D, Bacchetta M (2011) Extracorporeal membrane oxygenation for ARDS 
in adults. N Engl J Med 365:1903–1914

Cao B, Huang GH, Pu ZH, Qu JX, Yu XM, Zhu Z, Dong JP, Gao Y, Zhang YX, 
Li XH, Liu JH, Wang X, Xu Q, L H, Xu W, Wang C (2014) Emergence of 
community-acquired adenovirus type 55 as a cause of community-onset 
pneumonia. Chest 145:79–86

Cavagnaro F, Kattan J, Godoy L, Gonzales A, Vogel A, Rodriguez JL, Faunes M, 
Fajardo C, Becker P (2007) Continuous renal replacement therapy in neo-
 nates and young infants during extracorporeal membrane oxygenation. 
Int J Artif Organs 30:220–226

Chen H, Yu RG, Yin NN, Zhou JX (2014) Combination of extracorporeal 
membrane oxygenation and continuous renal replacement therapy in 
critically ill patients: a systematic review. Crit Care 18:675

Deutschman C, Neligan P (eds) (2016) Evidence-based practice of critical care. 
Elsevier, Philadelphia

Ferguson ND, Fan E, Camponota L, Antonelli M, Anzueto A, Beale R, Brochard L, 
Brower R, Esteban A,Gattinoni L, Rhodes A, Slutsky A, Vincent J, Ruben-
feld GD, Thompson BT, Ranieri VM (2012) The Berlin definition of ARDS: an 
expanded rationale, justification, and supplementary material. Intensive 
Care Med 38:1573–1582

From the Centers for Disease Control and Prevention (2001) Two fatal cases 
of adenovirus-related illness in previously healthy young adults. JAMA 
286:782–783

Gbadebesin R, Zhao S, Charpie J, Brophy PD, Smoyer WE, Lin JJ (2009) Signifi-
cance of hemolysis on extracorporeal membrane lung support after cardiac surgery in 
children. Pediatr Nephrol 24:589–595

Gu L, Liu Z, Lu X, Qu J, Guan W, Liu Y, Song S, Yu X, Cao B (2012) Severe commun-
ity-acquired pneumonia caused by adenovirus type 11 in immunocom-
potent adults in Beijing. J Clin Virol 54:295–301

Hirshberg E, Miller RR 3rd, Morris AH (2013) Extracorporeal membrane oxygena-
 tion in adults with acute respiratory distress syndrome. Curr Opin 
Crit Care 19:36–43

Hoover NG, Heard M, Reid C, Wagoner S, Rogers K, Folsand JL, Paden ML, 
Fortenberry JD (2008) Enhanced fluid management with continuous 
venovenous hemoﬁltration in pediatric respiratory failure patients receiv-
ing extracorporeal membrane oxygenation support. Intensive Care Med 
34:2241–2247

Kajon AE, Dickson LM, Metzgor D, Houng HS, Lee V, Tan BH (2010) Outbreak of 
febrile respiratory illness associated with adenovirus 11a infection in a 
Singapore military training camp. J Clin Microbiol 48:1438–1441

Kim SJ, Kim K, Park SB, Hong DJ, Jhun BW (2015) Outcomes of early administra-
tion of cidofovir in non-immunocompromised patients with severe 
adenovirus pneumonia. PLoS ONE 10:e0122642

Low SY, Tan TT, Lee CH, Loo CM, Chew HC (2013) Severe adenovirus pneumonia 
requiring extracorporeal membrane oxygenation support—serotype 
7 revisited. Respir Med 107:1810–1813

MacLaren G, Combes A, Bartlett RH (2012) Contemporary extracorporeal 
membrane oxygenation for adult respiratory failure: life support in 
the new era. Intensive Care Med 38:210–220

Morris AH (2012) Exciting new ECMO technology awaits compelling scientific 
evidence for widespread use in adults with respiratory failure. Intensive 
Care Med 38:186–188

Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF Jr, Weaver LK, Dean 
NC, Thomas F, East TD, Pace NL, Suchyta MR, Beck E, Bombino M, Sittig 
DF, Böhm S, Hoffmann B, Becks H, Butler S, Pearl J, Rasmussen B (1994) 
Randomized clinical trial of pressure-controlled inverse ratio ventilation 
and extracorporeal CO2 removal for adult respiratory distress syndrome. 
Am J Respir Crit Care Med 149:295–305

Morris AH, Hirshberg E, Miller RR 3rd, Statler KD, Hite RD (2010) Counterpoint: 
efficacy of extracorporeal membrane oxygenation in 2009 influenza 
A(H1N1): sufficient evidence? Chest 138:778–781

National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical 
Trials N, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden 
D, deBoisblanc B, Conners AF Jr, Hite RD, Harabin AL (2006) Comparison of 
two fluid-management strategies in acute lung injury. N Engl J Med 
354:2564–2575
Ha et al. SpringerPlus (2016) 5:1909

Park PK, Dalton HJ, Bartlett RH (2010) Point: efficacy of extracorporeal membrane oxygenation in 2009 influenza A(H1N1): sufficient evidence? Chest 138:776–778

Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalananey MM, Hibbert CL, Truessdale A, Clemens F, Cooper N, Firmin RK, Elbourne D, CESAR trial collaboration (2009) Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 374:1351–1363

Prodhan P, Bhutta AT, Gossett JM, Stroud MH, Rycus PT, Bratton SL, Fiser RT (2014) Extracorporeal membrane oxygenation support among children with adenovirus infection: a review of the Extracorporeal Life Support Organization registry. ASAIO J 60:49–56

Shi J, Chen Q, Yu W, Shen J, Gong J, He C, Hu Y, Zhang J, Gao T, Xi F, Li J (2014) Continuous renal replacement therapy reduces the systemic and pulmonary inflammation induced by venovenous extracorporeal membrane oxygenation in a porcine model. Artif Organs 38:215–223

Sun B, He H, Wang Z, Qu J, Li X, Ban C, Wan J, Cao B, Tong Z, Wang C (2014) Emergent severe acute respiratory distress syndrome caused by adenovirus type 55 in immunocompetent adults in 2013: a prospective observational study. Crit Care 18:456

Turner DA, Cheifetz IM (2013) Extracorporeal membrane oxygenation for adult respiratory failure. Respir Care 58:1038–1052

Wolf MJ, Chanani NK, Heard ML, Kanter KR, Mahle WT (2013) Early renal replacement therapy during pediatric cardiac extracorporeal support increases mortality. Ann Thorac Surg 96:917–922

Yang Z, Zhu Z, Tang L, Wang L, Tan X, Yu P, Zhang Y, Tian X, Wang J, Zhang Y, Li D, Xu W (2009) Genomic analyses of recombinant adenovirus type 11a in China. J Clin Microbiol 47:3082–3090

Yimin H, Wenkui Y, Jialiang S, Qiqi C, Juehong S, Zhilang L, Changsheng H, Ning L, Jieshou L (2013) Effects of continuous renal replacement therapy on renal inflammatory cytokines during extracorporeal membrane oxygenation in a porcine model. J Cardiothorac Surg 8:113

Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett RH, Edmunds LH, Morris AH, Peirce EC 2nd, Thomas AN, Proctor HJ, Drinker PA, Pratt PC, Bagnewski A, Miller RG Jr (1979) Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 242:2193–2196

Zhang Q, Seto D, Cao B, Zhao S, Wan C (2012) Genome sequence of human adenovirus type 55, a re-emergent acute respiratory disease pathogen in China. J Virol 86:12441–12442

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com